ViewsML Technologies

ViewsML is a digital health company focused on solving bottlenecks in pathology using AI machine learning to help speed up discovery and diagnosis.

[ViewsML Technologies @viewsML]

We’re getting ready for #PathVisions26, where we’ll share new data on the use of virtual staining for rapid NSCLC subtyping on Saturday, 10/17, 5:35-6:30pm (Session 4, Monitor 2)

If you’ll be at #PathVisions26, let's connect. Contact us: https://t.co/U5E4uhwXuL

[ViewsML Technologies @viewsML]

What if you could search your tissue archive for biomarker expression before even cutting a block?

Come see what our virtual biomarker staining can do for you -- within your existing workflow -- at the AATB Annual Meeting this week!

[ViewsML Technologies @viewsML]

Welcome Michael Rivers to our BoD! He brings 20+ years of experience leading the commercialization of global diagnostic & #digitalpathology portfolios, including advancing AI-enabled technologies from development to regulatory clearance & market adoption. https://t.co/biN55PjkOq

[ViewsML Technologies @viewsML]

Tissue is finite. Your archive shouldn’t be.

Visit us at AATB to learn how virtual staining generates biomarker expression data directly from existing H&E — without consuming additional tissue.

Come see how we can help you preserve tissue while getting more from your archive.

[ViewsML Technologies @viewsML]

ViewsML enables researchers to characterize the tumor microenvironment at single-cell resolution, at a scale that conventional multiplex assays can’t achieve.

Learn more: https://t.co/zQ4tLewhZl

[ViewsML Technologies @viewsML]

Visit our booth at AATB to learn how ViewsML’s virtual biomarker staining technology can help you unlock more insight from your existing H&E slides.

Save valuable time and resources by searching digitized H&E for precise biomarker expression.

https://t.co/vf6Ax0NIaM

[ViewsML Technologies @viewsML]

ViewsML predicted five biomarkers directly from H&E, demonstrating strong cell-level classification performance and correlation with physical immunohistochemistry. Learn more: https://t.co/zQ4tLewhZl

[ViewsML Technologies @viewsML]

What if a single H&E slide could reveal more of the #lungtumor microenvironment?
Our case study explores how ViewsML’s #VirtualBiomarkerStaining (vIHC) predicted 5 key TME biomarkers directly from H&E
Read the case study: https://t.co/zQ4tLewhZl

[ViewsML Technologies @viewsML]

We’re proud to be featured in @GenomeWeb's look at how #AI is transforming traditional #pathology and how our AI-driven #BiomarkerStaining creates a virtual equivalent of #immunohistochemistry: https://t.co/LWOGDfTUQa

[ViewsML Technologies @viewsML]

We’re proud to be part of the work of Dr. Charles Jeffrey Tan, Drug Development and Phase 1 Clinical Trial Fellow at Princess Margaret Cancer Centre, presented at AACR’s inaugural Drug Discovery and Development conference.
Read more from @oncodaily https://t.co/trZAhDCfGV

[ViewsML Technologies @viewsML]

Using ViewsML's data, @UHN’s @pmcancercentre validates AI-driven virtual PD-L1 immunohistochemistry for diagnostic accuracy. See us at the American Association for Cancer Research Drug Discovery and Development conference. https://t.co/U5E4uhwpFd

[ViewsML Technologies @viewsML]

Last week, @RandDWorld's Brian Buntz and our CEO, Kenneth To, explored how ViewsML’s virtual biomarker staining technology differs from traditional pathology AI tools.

Read the article: https://t.co/9Uxrv9L5NO

#VirtualBiomarkers #BiomarkerStaining #DigitalPathology

[ViewsML Technologies @viewsML]

Can AI accurately review virtual PD-L1 immunohistochemistry? @UHN’s @pmcancercentre findings feature ViewsML data at the American Association for Cancer Research Drug Discovery and Development conference. https://t.co/U5E4uhwpFd

[ViewsML Technologies @viewsML]

Our CEO, Kenneth To, spoke with @RandDWorld about how ViewsML is helping #biopharma unlock new #biomarker insights from routine H&E images through virtual biomarker staining —and discussed our recent $4.9M funding round with @MayoClinic as a new investor. https://t.co/9Uxrv9L5NO

[ViewsML Technologies @viewsML]

ViewsML contributes virtual biomarker staining data in @UHN’s @pmcancercentre's AI PD-L1 immunohistochemistry poster at the American Association for Cancer Research Drug Discovery and Development conference. https://t.co/U5E4uhwpFd

[ViewsML Technologies @viewsML]

ICYMI: Our co-founder and CEO, Kenneth To, shares in @pathologistmag how AI-driven virtual biomarker staining can turn H&E slides into a scalable source of layered insights—without disrupting existing #pathology workflows.
https://t.co/jU1M2pJzki

#DigitalPathology #Biomarkers

[ViewsML Technologies @viewsML]

Excited to be recognized as a @lifesciences_bc 2026 Company to Watch. We’re proud to be advancing computational pathology through virtual staining, creating a new digital layer to tissue analysis that enables faster and more scalable biomarker insights.
https://t.co/IaaAuDH5Sn

[ViewsML Technologies @viewsML]

In his article in @pathologistmag, our co-founder and CEO, Kenneth To, explores how AI-driven virtual #biomarker staining enables scalable biomarker analysis and what this means for some of #pathology’s most persistent bottlenecks. Read more: https://t.co/jU1M2pJzki

[ViewsML Technologies @viewsML]

Thrilled to partner with @DartmouthHealth to advance AI-driven virtual biomarkers! Our collaboration transforms pathology via virtual biomarker expression in minutes, preserving precious tissue while delivering richer insights. Full details in the release #digitalpathology

[ViewsML Technologies @viewsML]

ViewsML and Dartmouth Health Partner to Advance AI-Driven Virtual Biomarkers and Diagnostics https://t.co/HQhGcHjnZt via @ein_news 🧵